磷酸化脊髓小脑失调症蛋白1抗体

磷酸化脊髓小脑失调症蛋白1抗体Quantity size:

0.1ml

Concentration:

1mg/ml   Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Background:

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord.磷酸化脊髓小脑失调症蛋白1抗体 Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and 磷酸化脊髓小脑失调症蛋白1抗体unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains41-81 CAG repeats, compared to 6-39 in the normal allele, and is associated with spinocerebellar ataxia type 1 (SCA1). At least two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq].

Also known as:

Ataxin 1 (phospho S775); ATXN1; ATX1; D6S504E; SCA1; Ataxin-1; Spinocerebellar ataxia type 1; ATX1_HUMAN.

磷酸化脊髓小脑失调症蛋白1抗体Specificity:

●

Rabbit Polyclonal IgG, affinity purified by Protein A.

●

Reacts with: Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, .

●

Immunogen: KLH conjugated Synthesised phosphopeptide derived from human Ataxin-1 around the phosphorylation site of Ser775.

●

Predicted Molecular Weight: 90kDa.

磷酸化脊髓小脑失调症蛋白1抗体Storage:

Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).

Application:

WB=1:100-500  ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  ICC=1:100-500  IF=1:100-500   
Not yet tested in other applications. 
Optimal working dilutions must be determined by the end user.

kl037Ca01纤连蛋白(FN)多克隆抗体Polyclonal Antibody to Fibronectin (FN)

kl037Po01纤连蛋白(FN)多克隆抗体Polyclonal Antibody to Fibronectin (FN)

kl037Bo01纤连蛋白(FN)多克隆抗体Polyclonal Antibody to Fibronectin (FN)

kl037Cp01纤连蛋白(FN)多克隆抗体Polyclonal Antibody to Fibronectin (FN)

kl037Eq01纤连蛋白(FN)多克隆抗体Polyclonal Antibody to Fibronectin (FN)

kl610Ge01叶酸(FA)多克隆抗体Polyclonal Antibody to Folic Acid (FA)

kl759Ge01赤霉素(GA)多克隆抗体Polyclonal Antibody to Gibberellic Acid (GA)

kl084Hu01甘丙肽(GAL)多克隆抗体Polyclonal Antibody to Galanin (GAL)

kl084Mu01甘丙肽(GAL)多克隆抗体Polyclonal Antibody to Galanin (GAL)

kl084Ra01甘丙肽(GAL)多克隆抗体Polyclonal Antibody to Galanin (GAL)

kl900Ge01γ-氨基丁酸(γABA)多克隆抗体Polyclonal Antibody to Gamma-Aminobutyric Acid (gABA)

kl506Hu01胃泌素释放肽(GRP)多克隆抗体Polyclonal Antibody to Gastrin Releasing Peptide (GRP)

kl506Mu01胃泌素释放肽(GRP)多克隆抗体Polyclonal Antibody to Gastrin Releasing Peptide (GRP)

kl506Ra01胃泌素释放肽(GRP)多克隆抗体Polyclonal Antibody to Gastrin Releasing Peptide (GRP)

kl882Hu01胃泌素抑制肽(GIP)多克隆抗体Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP)

kl882Mu01胃泌素抑制肽(GIP)多克隆抗体Polyclonal Antibody to Gastric Inhibitory Polypeptide (GIP)